[go: up one dir, main page]

UY37969A - Formulaciones de peptidos de liberación sostenida - Google Patents

Formulaciones de peptidos de liberación sostenida

Info

Publication number
UY37969A
UY37969A UY0001037969A UY37969A UY37969A UY 37969 A UY37969 A UY 37969A UY 0001037969 A UY0001037969 A UY 0001037969A UY 37969 A UY37969 A UY 37969A UY 37969 A UY37969 A UY 37969A
Authority
UY
Uruguay
Prior art keywords
sustained release
formulations
setmelanotide
release peptides
pharmaceutical composition
Prior art date
Application number
UY0001037969A
Other languages
English (en)
Inventor
John Dey Michael
Jaya Gautam
T Henderson Barton
Markus Johnsson
Stina Lindman
Original Assignee
Rhythm Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhythm Pharmaceuticals Inc filed Critical Rhythm Pharmaceuticals Inc
Publication of UY37969A publication Critical patent/UY37969A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta divulgación proporciona, al menos en parte un producto farmacéutico que comprende setmelanotide; u otra composición farmacéutica que tiene su mecanismo de acción principal en el receptor MC4 como un agonista y un excipiente, por ejemplo, un excipiente lipídico, y / o un vehículo farmacéuticamente aceptable. El producto farmacéutico descrito en el presente documento proporciona una liberación sostenida de setmelanotide u otra composición farmacéutica, que puede dar como resultado un perfil farmacocinético y farmacodinámico más deseable tras la administración.
UY0001037969A 2017-11-15 2018-11-15 Formulaciones de peptidos de liberación sostenida UY37969A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762586643P 2017-11-15 2017-11-15

Publications (1)

Publication Number Publication Date
UY37969A true UY37969A (es) 2019-06-28

Family

ID=66539115

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037969A UY37969A (es) 2017-11-15 2018-11-15 Formulaciones de peptidos de liberación sostenida

Country Status (15)

Country Link
US (1) US20210169965A1 (es)
EP (1) EP3710041A4 (es)
JP (2) JP2021502983A (es)
KR (1) KR20200135280A (es)
CN (1) CN112188898A (es)
AR (1) AR113885A1 (es)
AU (1) AU2018370039A1 (es)
BR (1) BR112020009648A2 (es)
CA (1) CA3082708A1 (es)
IL (1) IL274689A (es)
MX (1) MX2020005117A (es)
SG (1) SG11202004373RA (es)
TW (1) TW201922278A (es)
UY (1) UY37969A (es)
WO (1) WO2019099735A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3539551B1 (en) 2011-12-29 2021-10-06 Rhythm Pharmaceuticals, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
WO2018106859A1 (en) 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
CN113993535B (zh) * 2019-05-29 2025-03-14 卡姆拉斯公司 脂质控释组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
NZ551990A (en) * 2004-06-04 2011-01-28 Camurus Ab Liquid depot formulations
JP5250026B2 (ja) 2007-05-25 2013-07-31 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ヒダントインで修飾したメラノコルチン受容体リガンド
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations
PT2714004T (pt) * 2011-05-25 2024-07-12 Camurus Ab Formulações de peptídeos de libertação controlada
KR101494594B1 (ko) * 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
EP3539551B1 (en) 2011-12-29 2021-10-06 Rhythm Pharmaceuticals, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
CN115957296A (zh) * 2013-03-15 2023-04-14 节奏制药公司 药物组合物
EA033590B1 (ru) * 2014-12-23 2019-11-07 Camurus Ab Препараты с контролируемым высвобождением
ES2985734T3 (es) 2015-09-30 2024-11-07 Rhythm Pharmaceuticals Inc Método de tratamiento de trastornos asociados a la vía del receptor de la melanocortina-4

Also Published As

Publication number Publication date
BR112020009648A2 (pt) 2020-11-10
JP2024026333A (ja) 2024-02-28
TW201922278A (zh) 2019-06-16
AU2018370039A1 (en) 2020-05-21
US20210169965A1 (en) 2021-06-10
EP3710041A4 (en) 2021-08-18
IL274689A (en) 2020-06-30
KR20200135280A (ko) 2020-12-02
RU2020119425A (ru) 2021-12-15
JP2021502983A (ja) 2021-02-04
CA3082708A1 (en) 2019-05-23
SG11202004373RA (en) 2020-06-29
WO2019099735A1 (en) 2019-05-23
MX2020005117A (es) 2020-11-24
AR113885A1 (es) 2020-06-24
CN112188898A (zh) 2021-01-05
EP3710041A1 (en) 2020-09-23

Similar Documents

Publication Publication Date Title
UY37969A (es) Formulaciones de peptidos de liberación sostenida
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
IL304521A (en) GPCR receptor agonists, pharmaceutical preparations containing them and methods of using them
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
CL2007002356A1 (es) Sistema de liberacion farmaceutica que comprende flibanserina y por lo menos un excipiente farmaceuticamentre aceptable; y su uso para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, del sueno y sexuales, entre otros.
PA8815501A1 (es) Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa
CR20110110A (es) Composicion farmaceutica
GT200600500A (es) Composición farmacéutica orodispersable para la administración oromucosal o sublingual de la agomelatina
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
BR112012022797A2 (pt) composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool
DOP2016000262A (es) Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación
AR057946A1 (es) Formulacion de zonisamida de liberacion sostenidda
CR20160438A (es) Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación
ECSP19035322A (es) Formulaciones farmacéuticas
ZA201902051B (en) Pharmaceutical composition
MX2018008300A (es) Formulacion para anticuerpo y conjugado de farmaco del mismo.
CL2008000617A1 (es) Composicion farmaceutica que comprende a un agente calcilitico adminstrado oralmente, induce liberacion rapida y de corta duracion de la hormona paratiroide en el plasma; y proceso para la preparacion de la composicion farmaceutica.
PH12017502426A1 (en) Solid pharmaceutical compositions for treating hcv
EA201991265A1 (ru) Лекарственные формы с отсроченным высвобождением, содержащие диметилфумарат
ECSP18008411A (es) Composiciones farmacéuticas sólidas para el tratamiento del vhc
CL2007002797A1 (es) Composicion terapeutica que comprende un anticuerpo contra el receptor del egf, interferon y excipientes adecuados para su administracion por via intravenosa.
BR112021023012A2 (pt) Coformulações injetáveis à base de ciclodextrina de inibidores de sglt2 e peptídeos de incretina
CL2019001555A1 (es) Preparación farmacéutica y método para su fabricación.
CL2021003497A1 (es) Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1
CR20130288A (es) Comprimido farmacéutico de liberación controlada para administración oral